Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition.
| Title: | Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition. |
|---|---|
| Authors: | Höglund A; Department of Molecular Biology, Umeå University, Umeå, Sweden.; Strömvall K; Li Y; Forshell LP; Nilsson JA |
| Source: | Cell cycle (Georgetown, Tex.) [Cell Cycle] 2011 Oct 15; Vol. 10 (20), pp. 3598-607. Date of Electronic Publication: 2011 Oct 15. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101137841 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1551-4005 (Electronic) Linking ISSN: 15514005 NLM ISO Abbreviation: Cell Cycle Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2015- : Philadelphia, PA : Taylor & Francis; Original Publication: Georgetown, TX : Landes Bioscience, c2002- |
| MeSH Terms: | Poly(ADP-ribose) Polymerase Inhibitors*; Apoptosis/*genetics ; DNA Damage/*genetics ; Lymphoma/*metabolism ; Protein Serine-Threonine Kinases/*deficiency ; Proto-Oncogene Proteins c-myc/*metabolism; Protein Serine-Threonine Kinases/antagonists & inhibitors ; Thiophenes/pharmacology ; Urea/analogs & derivatives ; Urea/pharmacology ; Animals ; Cell Line ; Checkpoint Kinase 2 ; Fluorescent Antibody Technique ; Humans ; Lentivirus ; Mice ; Mice, Inbred C57BL ; Mice, Mutant Strains ; NIH 3T3 Cells ; Poly (ADP-Ribose) Polymerase-1 ; Retroviridae ; Reverse Transcriptase Polymerase Chain Reaction ; Survival Analysis ; Transfection |
| Abstract: | Myc is a transcription factor frequently found deregulated in human cancer. The Myc-mediated cellular transformation process is associated with fast proliferative cells and inherent genomic instability, giving rise to malignant, invasive neoplasms with poor prognosis for survival. Transcription-independent functions of Myc include stimulation of replication. Excessive Myc expression stimulates a replication-associated DNA damage response that signals via the phosphoinositide-3-kinase (PI3K)-related protein kinases (PIKKs) ATM and ATR. These, in turn, activate the DNA damage transducers Chk1 and Chk2. Here, we show that Myc can stimulate Chek2 transcript indirectly in vitro as well as in B cells of λ-Myc transgenic mice or in the intestine of Apc (Min) mice. However, Chk2 is dispensable for Myc's ability to transform cells in vitro and for the survival of established lymphoma cells from λ-Myc transgenic mice. Chk2 deficiency induces polyploidy and slow growth, but the cells are viable and protected against DNA damage. Furthermore, inhibition of both Chk1/Chk2 with AZD7762 induces cell death and significantly delays disease progression of transplanted lymphoma cells in vivo. DNA damage recruits PARP family members to sites of DNA breaks that, in turn, facilitate the induction of DNA repair. Strikingly, combining Chk2 and PARP inhibition elicits a synergistic lethal response in the context of Myc overexpression. Our data indicates that only certain types of chemotherapy would give rise to a synergistic lethal response in combination with specific Chk2 inhibitors, which will be important if Chk2 inhibitors enter the clinic. |
| References: | Science. 1999 Dec 24;286(5449):2528-31. (PMID: 10617473); Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7804-8. (PMID: 8356088); Mol Cancer. 2004 May 04;3:14. (PMID: 15125777); Dev Cell. 2007 Feb;12(2):247-60. (PMID: 17276342); Nature. 2005 Apr 14;434(7035):913-7. (PMID: 15829966); Cancer Res. 2001 Nov 1;61(21):7727-30. (PMID: 11691784); J Biol Chem. 2002 May 31;277(22):19389-95. (PMID: 11901158); Genes Dev. 2000 Jun 15;14(12):1439-47. (PMID: 10859163); Oncogene. 2004 Nov 4;23(52):8535-44. (PMID: 15361853); Pharmacol Rev. 2006 Sep;58(3):621-81. (PMID: 16968952); Cancer Prev Res (Phila). 2010 Feb;3(2):140-7. (PMID: 20103729); Aging (Albany NY). 2010 Apr;2(4):244-50. (PMID: 20445224); Nature. 2005 Apr 14;434(7035):907-13. (PMID: 15829965); Biochim Biophys Acta. 2010 Mar;1803(3):386-95. (PMID: 20080130); Clin Cancer Res. 2008 Jul 1;14(13):4032-7. (PMID: 18593978); Cell. 2006 Nov 3;127(3):539-52. (PMID: 17081976); Nat Rev Mol Cell Biol. 2006 Jul;7(7):517-28. (PMID: 16829982); Clin Cancer Res. 2006 Dec 1;12(23):6967-72. (PMID: 17145815); Cell. 1997 Feb 7;88(3):323-31. (PMID: 9039259); Cell Cycle. 2010 Jul 1;9(13):2647-56. (PMID: 20581449); Mol Cancer Ther. 2008 Sep;7(9):2955-66. (PMID: 18790776); Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230); Cancer Res. 2006 Feb 15;66(4):1923-8. (PMID: 16488990); Science. 1992 May 1;256(5057):668-70. (PMID: 1350108); Clin Cancer Res. 2007 May 1;13(9):2728-37. (PMID: 17473206); Mol Cell Biol. 2004 Jan;24(2):708-18. (PMID: 14701743); Blood. 2010 Sep 2;116(9):1498-505. (PMID: 20519624); Cancer Res. 2006 Feb 1;66(3):1401-8. (PMID: 16452195); Blood. 2009 Apr 30;113(18):4281-8. (PMID: 19179467); Nature. 2005 Apr 14;434(7035):917-21. (PMID: 15829967); Cancer Res. 2011 Jan 15;71(2):463-72. (PMID: 21239475); Nat Cell Biol. 2010 May;12(5):492-9. (PMID: 20364141); Mol Cancer Ther. 2009 Jan;8(1):45-54. (PMID: 19139112); Genes Dev. 2000 Jun 15;14(12):1448-59. (PMID: 10859164); Nat Rev Mol Cell Biol. 2010 Feb;11(2):138-48. (PMID: 20029420); Nat Rev Cancer. 2003 Mar;3(3):155-68. (PMID: 12612651); FEBS Lett. 2001 Sep 7;505(1):7-12. (PMID: 11557032); Genes Dev. 2000 Feb 1;14(3):289-300. (PMID: 10673501); Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):12983-8. (PMID: 9789027); Mol Cancer Ther. 2007 Mar;6(3):935-44. (PMID: 17363488); Nucleic Acids Res. 1995 May 25;23(10):1686-90. (PMID: 7784172); Science. 2000 Mar 10;287(5459):1824-7. (PMID: 10710310); Semin Cancer Biol. 2006 Aug;16(4):253-64. (PMID: 16904903); Clin Cancer Res. 2011 Nov 15;17(22):7067-79. (PMID: 21933891); Biochem Cell Biol. 2007 Aug;85(4):509-20. (PMID: 17713585); Cancer Cell. 2003 May;3(5):421-9. (PMID: 12781359); Mol Cell Biol. 2003 Oct;23(20):7256-70. (PMID: 14517295); Mol Cancer Ther. 2003 Apr;2(4):371-82. (PMID: 12700281); Nat Cell Biol. 2005 Feb;7(2):195-201. (PMID: 15665856); Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10389-94. (PMID: 10973490); Oncogene. 2003 Dec 8;22(56):9007-21. (PMID: 14663479); Nature. 2001 Apr 12;410(6830):842-7. (PMID: 11298456); Aging (Albany NY). 2009 May 20;1(5):458-69. (PMID: 20157531); Ann Oncol. 2004;15 Suppl 1:I7-I13. (PMID: 15280181); Oncotarget. 2011 Jun;2(6):448-60. (PMID: 21646687); Genes Chromosomes Cancer. 1999 Oct;26(2):176-80. (PMID: 10469457); EMBO J. 2002 Oct 1;21(19):5195-205. (PMID: 12356735); Oncogene. 1999 Jul 15;18(28):4047-54. (PMID: 10435585); Science. 1998 Sep 4;281(5382):1509-12. (PMID: 9727977); Aging (Albany NY). 2010 Dec;2(12):900-7. (PMID: 21191148); Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3745-50. (PMID: 10097108); Nature. 2007 Jul 26;448(7152):445-51. (PMID: 17597761) |
| Substance Nomenclature: | 0 (3-(carbamoylamino)-5-(3-fluorophenyl)-N-(3-piperidyl)thiophene-2-carboxamide); 0 (Myc protein, mouse); 0 (Poly(ADP-ribose) Polymerase Inhibitors); 0 (Proto-Oncogene Proteins c-myc); 0 (Thiophenes); 8W8T17847W (Urea); EC 2.4.2.30 (Parp1 protein, mouse); EC 2.4.2.30 (Poly (ADP-Ribose) Polymerase-1); EC 2.7.1.11 (Checkpoint Kinase 2); EC 2.7.11.1 (CHEK2 protein, human); EC 2.7.11.1 (Chek2 protein, mouse); EC 2.7.11.1 (Protein Serine-Threonine Kinases) |
| Entry Date(s): | Date Created: 20111028 Date Completed: 20120320 Latest Revision: 20211203 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC3266184 |
| DOI: | 10.4161/cc.10.20.17887 |
| PMID: | 22030621 |
| Database: | MEDLINE |
Journal Article; Research Support, Non-U.S. Gov't